From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases DME Interactive Data Deep Dive

From Promise to Progress: More Durable Treatments for Neovascular Retinal Diseases DME Interactive Data Deep Dive is organized by Paradigm Medical Communications, LLC.,Release Date: September 29, 2022,Expiration Date: September 29, 2023,Program Overview:,This engaging infographic activity will take learners on an interactive, multimedia journey through the pivotal phase 3 trials that led to the recent FDA approval of faricimab for the treatment of diabetic macular edema (DME). Because faricimab differs significantly from anti-VEGF, a thorough understanding of key data and contextualization by experts will be crucial in elucidating the role of faricimab and appropriately integrating this novel therapy into clinical practice.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Articulate clinical trial designs of recently available novel therapies that are indicated for the treatment of neovascular retinal diseases,• Summarize safety and efficacy data for recently available novel treatments for neovascular retinal diseases.